Praluent

Alimumab Praluent (alirocumab) is a human monoclonal antibody. It works by helping the liver reduce the levels of "bad" cholesterol (low-density lipoprotein, or LDL) circulating in the blood.

Alimumab is used in adults with heart disease to reduce the risk of heart attack, stroke, and certain types of chest pain conditions that require hospitalization (unstable angina).

Alizumab is used with a low-fat diet, alone or with other cholesterol-lowering drugs, in adults with high blood cholesterol levels called primary hyperlipidemia (including a type of high cholesterol called heterozygous familial hypercholesterolemia), which is an inherited type of high cholesterol. This condition can cause blood Elevated levels of LDL cholesterol can also cause plaque to form in the arteries.

Alimumab is also used along with other LDL-lowering treatments in adults with a form of high cholesterol called homozygous familial hypercholesterolemia who need further lowering of LDL-C.

Arinab dosage information

Usual adult dosage for hyperlipidemia:

75 mg subcutaneously every 2 weeks or 300 mg subcutaneously every 4 weeks

- For inadequate LDL-C (low-density lipoprotein) response, the dose may be adjusted to 150 mg subcutaneously every 2 weeks

Maximum dose: 150 subcutaneously every 2 weeks mg

Hypercholesterolemia (HeFH) in heterozygous familial patients undergoing LDL apheresis: 150 mg SC every 2 weeks; dosing may be given regardless of timing of apheresis

Comments:

-Assess LDL-C when clinically appropriate, which may be as early as after initiation of therapy LDL-C lowering effects were measured at 4 weeks.

- In some patients, LDL-C may vary significantly during the 4-week dosing interval, so measure LDL-C before the next scheduled dose.

- If LDL-C reduction is insufficient, consider starting a new dose on the next scheduled dosing date and titrate the dose to 150 mg every 2 weeks.

Uses:

- As an adjunct to diet, alone or in combination with other lipid-lowering therapies, for the treatment of primary hyperlipidemia, including HeFH to lower LDL-C.

- Reduces the risk of myocardial infarction, stroke and unstable angina requiring hospitalization in adults with established cardiovascular disease.

Usual adult dosage for heterozygous familial hypercholesterolemia:

75 mg subcutaneously every 2 weeks or 300 mg subcutaneously every 4 weeks

-For inadequate LDL-C (low-density lipoprotein) response, the dose may be adjusted to 150 mg subcutaneously every 2 weeks

Maximum dose: 150 subcutaneously every 2 weeks mg

Hypercholesterolemia (HeFH) in heterozygous familial patients undergoing LDL apheresis: 150 mg SC every 2 weeks; dose may be given regardless of timing of apheresis

Comments:

- Assess LDL-C when clinically appropriate, with reductions measured as early as 4 weeks after initiation of therapy Effects of LDL-C.

- In some patients, LDL-C may vary significantly during the 4-week dosing interval, so measure LDL-C before the next scheduled dose.

- If LDL-C reduction is insufficient, consider starting a new dose on the next scheduled dosing date and titrate the dose to 150 mg every 2 weeks.

Uses:

- As an adjunct to diet, alone or in combination with other lipid-lowering therapies, for the treatment of primary hyperlipidemia, including HeFH to lower LDL-C.

- Reduces the risk of myocardial infarction, stroke and unstable angina requiring hospitalization in adults with established cardiovascular disease.

Alimumab Side Effects

If you have symptoms of a severe allergic reaction to alimumab, get emergency medical help. Reactions include anaphylaxis, hives, severe itching; difficulty breathing; swelling of the face, lips, tongue, or throat.

Common alimumab side effects may include: redness, itching, soreness, or swelling at the injection site; flu symptoms; or cold symptoms such as nasal congestion, sneezing, and sore throat.